Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Shares Outstanding: 2017-2022

Historic Shares Outstanding for Cidara Therapeutics (CDTX) over the last 4 years, with Jun 2022 value amounting to $69.2 million.

  • Cidara Therapeutics' Shares Outstanding rose 39.86% to $69.2 million in Q2 2022 from the same period last year, while for Jun 2022 it was $69.2 million, marking a year-over-year increase of 39.86%. This contributed to the annual value of $67.9 million for FY2021, which is 51.22% up from last year.
  • According to the latest figures from Q2 2022, Cidara Therapeutics' Shares Outstanding is $69.2 million, which was up 0.27% from $69.0 million recorded in Q1 2022.
  • In the past 5 years, Cidara Therapeutics' Shares Outstanding registered a high of $69.2 million during Q2 2022, and its lowest value of $21.4 million during Q1 2018.
  • Over the past 3 years, Cidara Therapeutics' median Shares Outstanding value was $48.9 million (recorded in 2021), while the average stood at $52.5 million.
  • In the last 5 years, Cidara Therapeutics' Shares Outstanding dropped by 3.29% in 2019 and then spiked by 56.98% in 2020.
  • Cidara Therapeutics' Shares Outstanding (Quarterly) stood at $27.8 million in 2018, then climbed by 21.65% to $33.8 million in 2019, then skyrocketed by 32.62% to $44.9 million in 2020, then skyrocketed by 51.22% to $67.9 million in 2021, then soared by 39.86% to $69.2 million in 2022.
  • Its Shares Outstanding stands at $69.2 million for Q2 2022, versus $69.0 million for Q1 2022 and $67.9 million for Q4 2021.